Physician profile
Joi Hester
NPI 1659805133
$8,787.15
in general payments reported to CMS, 2019-2025
33 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,839 · 2020: $14.15 · 2022: $53.37 · 2024: $227 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.61 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $5,785.00 | 2019 | |
| Insulet Corporation | $433.98 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $249.33 | 2019-2025 | |
| Mannkind Corporation | $214.90 | 2024-2025 | |
| Valeritas, INC. | $183.27 | 2019 | |
| Abbott Laboratories | $176.18 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $175.13 | 2024-2025 | Tepezza, Evenity, Repatha |
| Lilly USA, LLC | $167.66 | 2019-2025 | Zepbound, Mounjaro |
| Recordati_rare_diseases_inc. | $139.56 | 2025 | Isturisa |
| Soleno Therapeutics, INC. | $119.16 | 2025 | Vykat Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.79 | 2019-2025 | Jardiance |
| Medtronic, INC. | $100.36 | 2024-2025 | Minimed 780g, Simplera Sensor |
| Tandem Diabetes Care, INC. | $95.06 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $92.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $82.46 | 2019-2025 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $80.42 | 2025 | |
| Abbvie INC. | $66.83 | 2019-2025 | |
| Corcept Therapeutics | $60.13 | 2019 | |
| Novo Nordisk INC | $56.23 | 2025 | Ozempic, Rybelsus |
| Ge Healthcare | $53.37 | 2022 | |
| Ascendis Pharma Endocrinology INC | $46.38 | 2025 | Yorvipath |
| Radius Health, INC. | $40.95 | 2025 | Tymlos |
| Shire North American Group INC | $40.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.59 | 2019 | |
| Sequel Med Tech, LLC | $32.37 | 2025 | Twiist |
| Kyowa Kirin, INC. | $28.56 | 2025 | |
| Almatica Pharma LLC | $24.37 | 2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $19.21 | 2025 | Imcivree |
| Aimmune Therapeutics, INC. | $15.81 | 2025 | Zenpep |
| Medtronic Minimed, INC. | $14.72 | 2019 | |
| Merck Sharp & Dohme LLC | $13.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joi Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.